Publication Name	World Journal of Clinical Cases
Manuscript ID	13513
Country

Received	2014-08-26 08:46
Peer-Review Started	2014-08-26 17:46
To Make the First Decision	2014-09-28 12:26
Return for Revision	2014-09-30 08:25
Revised
Second Decision	2015-07-29 16:15
Accepted by Journal Editor-in-Chief
Accepted by Executive Editor-in-Chief	2015-08-07 16:15
Articles in Press	2015-08-07 16:15
Publication Fee Transferred
Edit the Manuscript by Language Editor
Typeset the Manuscript	2015-10-24 16:50
Publish the Manuscript Online	2015-11-11 16:43

ISSN	2307-8960 (online)
Open Access	Open-Access: This article is an open-access article which was selected by an in-house editor and fully peer-reviewed by external reviewers. It is distributed in accordance with the Creative Commons Attribution Non Commercial (CC BY-NC 4.0) license, which permits others to distribute, remix, adapt, build upon this work non-commercially, and license their derivative works on different terms, provided the original work is properly cited and the use is non-commercial. See: http://creativecommons.org/licenses/by-nc/4.0/
Copyright	© The Author(s) 2015. Published by Baishideng Publishing Group Inc. All rights reserved.
Article Reprints	For details, please visit: http://www.wjgnet.com/bpg/gerinfo/247
Permissions	For details, please visit: http://www.wjgnet.com/bpg/gerinfo/207
Publisher	Baishideng Publishing Group Inc, 7041 Koll Center Parkway, Suite 160, Pleasanton, CA 94566, USA
Website	http://www.wjgnet.com

Category	Infectious Diseases
Manuscript Type	Evidence-Based Medicine
Article Title	Cost-effectiveness in Clostridium difficile treatment decision-making
Manuscript Source	Unsolicited Manuscript
All Author List	Mark JC Nuijten, Josbert J Keller, Caroline E Visser, Ken Redekop, Eric Claassen, Peter Speelman and Marja H Pronk
Funding Agency and Grant Number
Corresponding Author	Mark JC Nuijten, PhD, MD, MBA, Ars Accessus Medica, Dorpsstraat 75, 1546 LG Jisp, The Netherlands. marknuijten@planet.nl
Key Words	Clostridium difficile infection; Guidance; Cost-effectiveness; Model; Standardisation; Decision making
Core Tip	Current clinical guidelines seldom include cost-effectiveness evaluations. Conclusions are typically based on clinical data only and sometimes referral is made to prices of therapies for justification of the treatment sequence advised. However, the price of a therapy as such is just a single criterion and does not reflect the balance between effectiveness and costs associated with the application of that therapy. This results often in a restricted position of new therapies in the treatment algorithm. Integration of cost-effectiveness using the population-based variant of cost-effectiveness evaluations as an instrument in guidelines for Clostridium difficile infection may be provide better decision making framework.
Publish Date	2015-11-11 16:43
Citation	Nuijten MJC, Keller JJ, Visser CE, Redekop K, Claassen E, Speelman P, Pronk MH. Cost-effectiveness in Clostridium difficile treatment decision-making. World J Clin Cases 2015; 3(11): 935-941
URL	http://www.wjgnet.com/2307-8960/full/v3/i11/935.htm
DOI	http://dx.doi.org/10.12998/wjcc.v3.i11.935

Full Article (PDF)	WJCC-3-935.pdf
Full Article (Word)	WJCC-3-935.doc
Manuscript File	13513-Review.doc
Answering Reviewers	13513-Answering reviewers.pdf
Audio Core Tip	13513-Audio core tip.mp3
Biostatistics Review Certificate	13513-Biostatistics statement.pdf
Conflict-of-Interest Disclosure Form	13513-Conflict-of-interest statement.pdf
Copyright License Agreement	13513-Copyright assignment.pdf
Peer-review Report	13513-Peer-review(s).pdf
Scientific Misconduct Check	13513-Scientific misconduct check.pdf
Scientific Editor Work List	13513-Scientific editor work list.pdf